Sarepta Therapeutics (SRPT) EBT (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly EBT of $343.2 million for Q1 2026, up 189.48% year-over-year from $118.5 million in Q1 2025, and up 223.31% quarter-over-quarter from -$278.3 million in Q4 2025.
Sarepta Therapeutics (SRPT) EBT (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' EBT history runs 17 years deep, the most recent figure standing at $343.2 million for Q1 2026.
- In Q1 2026, EBT rose 189.48% year-over-year to $343.2 million; the TTM figure through Mar 2026 stood at $24.5 million (up 114.9% YoY), while the FY2025 annual figure was -$702.2 million, down 369.28% from the prior year.
- EBT for Q1 2026 stood at $343.2 million, up from -$278.3 million in the prior quarter.
- The five-year high for EBT was $343.2 million in Q1 2026, with the low at -$512.7 million in Q1 2023.
- The 5-year median for EBT is -$14.6 million (2023), against an average of -$51.2 million.
- Peak annual rise in EBT reached 1031.6% in 2025, while the deepest fall reached 1025.3% in 2025.
- Sarepta Therapeutics' EBT stood at $337.3 million in 2022, then slumped by 88.03% to $40.4 million in 2023, then soared by 325.41% to $171.7 million in 2024, then plunged by 262.04% to -$278.3 million in 2025, then jumped by 223.31% to $343.2 million in 2026.
- Business Quant data shows SRPT's EBT at $343.2 million in Q1 2026, -$278.3 million in Q4 2025, and -$194.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.75 Mn |
| Mar 31, 2026 | 343.17 Mn |
| Dec 31, 2025 | -278.30 Mn |
| Sep 30, 2025 | -194.05 Mn |
| Jun 30, 2025 | 153.64 Mn |
| Mar 31, 2025 | -383.52 Mn |
| Dec 31, 2024 | 171.74 Mn |
| Sep 30, 2024 | 34.01 Mn |
| Jun 30, 2024 | 13.58 Mn |
| Mar 31, 2024 | 41.45 Mn |
| Dec 31, 2023 | 40.37 Mn |
| Sep 30, 2023 | -33.17 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -512.71 Mn |
| Dec 31, 2022 | 337.27 Mn |
| Sep 30, 2022 | -256.42 Mn |
| Jun 30, 2022 | -228.09 Mn |
| Mar 31, 2022 | -104.15 Mn |
| Dec 31, 2021 | -121.89 Mn |
| Sep 30, 2021 | -47.91 Mn |